Lamotrigine loaded poly-ε-(D,L-lactide-co-caprolactone) nanoparticles as brain delivery system

被引:31
|
作者
Ammar, Hussein O. [1 ,2 ]
Ghorab, Mahmoud M. [3 ]
Mahmoud, Azza A. [1 ,2 ]
Higazy, Iman M. [1 ]
机构
[1] Natl Res Ctr, Dept Pharmaceut Technol, Cairo, Egypt
[2] Future Univ Egypt, Dept Pharmaceut & Pharmaceut Technol, New Cairo, Egypt
[3] Cairo Univ, Dept Pharmaceut & Ind Pharm, Fac Pharm, Cairo, Egypt
关键词
Nanoparticles; poly-epsilon-(D-L-lactide-co-caprolactone); Lamotrigine; Brain delivery; Particle size; Drug release; Pharmacokinetics; PERFORMANCE LIQUID-CHROMATOGRAPHY; SOLVENT DIFFUSION METHOD; ANTIEPILEPTIC DRUGS; LIPID NANOPARTICLES; IN-VITRO; MICROSPHERES; NANOCAPSULES; FORMULATION; POLYMERS; CARRIERS;
D O I
10.1016/j.ejps.2018.01.028
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Management of epilepsy requires brain delivery therapy, therefore, this study was aimed to prepare lamotrigine loaded poly-epsilon-(D, L-lactide-co-caprolactone) (PLCL) nanoparticles using spontaneous emulsification solvent diffusion method. Nanoparticles for brain delivery required to have a particle size<200 nm, polydispesity index<0.2 and a sustained drug release properties. For such aim different factors were considered in preparing the nanoparticles as PLCL monomers' ratio, type of organic solvent used to prepare the nanoparticles, amount of PLCL and Pluronic (R) F127 in the nanoparticles. Prepared nanoparticles were characterized for their shape, particle size, polydispersity index, zeta potential, encapsulation efficiency, drug loading capacity, process yield and in-vitro drug release pattern. The in-vivo investigation for brain delivery of selected nanoparticles delivered by intravenous route was investigated in rats and compared to that for oral tablet. The obtained nanoparticles were spherical in shape. The amount of surfactant and PLCL affected the properties of the obtained nanoparticles. Using a mixture of organic solvent in preparing the nanoparticles improved its properties. The nanoparticles prepared using PLCL with monomers' ratio of 25: 75, had particle size value of 125 nm, polydispersity index value of 0.184, zeta potential value of -39 mV and encapsulation efficiency value of 99%, was selected to study their efficacy to deliver the drug to the brain. The tested nanoparticles showed higher values of T-max, C-max, AUC, and MRT in homogenized rat brain, compared to oral lamotrigine tablet, while the bioavailability of the oral tablet was higher in rat plasma compared to that for the nanoparticles. This reflects that brain was the main distribution site for tested nanoparticles, and plasma was the main distribution site for oral tablets. This confirms the goal of the selected formulation as brain delivery nanoparticles.
引用
收藏
页码:77 / 87
页数:11
相关论文
共 50 条
  • [21] Vascularization Potential of Electrospun Poly(L-Lactide-co-Caprolactone) Scaffold: The Impact for Tissue Engineering
    Jundzill, Arkadiusz
    Pokrywczynska, Marta
    Adamowicz, Jan
    Kowalczyk, Tomasz
    Nowacki, Maciej
    Bodnar, Magdalena
    Marszalek, Andrzej
    Frontczak-Baniewicz, Malgorzata
    Mikulowski, Grzegorz
    Kloskowski, Tomasz
    Gatherwright, James
    Drewa, Tomasz
    MEDICAL SCIENCE MONITOR, 2017, 23 : 1540 - 1551
  • [22] Preparation and properties of poly(l-lactide-co-caprolactone) random copolymer with high molecular weight
    School of Materials Science and Engineering, South China University of Technology, National Engineering Research Center for Tissue Restoration and Reconstruction, Guangzhou
    510641, China
    不详
    410004, China
    Gaofenzi Cailiao Kexue Yu Gongcheng, 6 (1-6 and 12):
  • [23] Poly (L-lactide-co-caprolactone) scaffolds enhanced with poly (β-hydroxybutyrateco-β-hydroxyvalerate) microspheres for cartilage regeneration
    Li, Chao
    Zhang, Jingjing
    Li, Yijiang
    Moran, Shamus
    Khang, Gilson
    Ge, Zigang
    BIOMEDICAL MATERIALS, 2013, 8 (02)
  • [24] Diphtheria toxoid loaded poly-(ε-caprolactone) nanoparticles as mucosal vaccine delivery systems
    Singh, J
    Pandit, S
    Bramwell, VW
    Alpar, HO
    METHODS, 2006, 38 (02) : 96 - 105
  • [25] Characterization, degradation, and mechanical strength of poly(D,L-lactide-co-ε-caprolactone)-poly(ethylene glycol)-poly(D,L-lactide-co-ε-caprolactone)
    Bramfeldt, Hanna
    Sarazin, Pierre
    Vermette, Patrick
    JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A, 2007, 83A (02) : 503 - 511
  • [26] Esophageal epithelium regeneration on fibronectin grafted poly(L-lactide-co-caprolactone) (PLLC) nanofiber scaffold
    Zhu, Yabin
    Leong, Meng Fatt
    Ong, Wey Feng
    Chan-Park, Mary B.
    Chian, Kerm Sin
    BIOMATERIALS, 2007, 28 (05) : 861 - 868
  • [27] Development of three-dimensionally printed vascular stents of bioresorbable poly(l-lactide-co-caprolactone)
    Zhao, Justin
    Song, Ge
    Zhao, Qinghua
    Feng, Hanqing
    Wang, Yunbing
    Anderson, James M.
    Zhao, Hugh
    Liu, Qing
    JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART B-APPLIED BIOMATERIALS, 2023, 111 (03) : 656 - 664
  • [28] Effect of electrospun poly (L-lactide-co-caprolactone) and formulated porcine fibrinogen for diabetic foot ulcers
    Wang, Guili
    Li, Xiaoyan
    Ju, Shuai
    Li, Yao
    Li, Wenqiang
    He, Hongbing
    Cai, Yunmin
    Dong, Zhihui
    Fu, Weiguo
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2024, 198
  • [29] Micropatterned poly(D,L-lactide-co-caprolactone) films entrapped with gelatin for promoting the alignment and directional migration of Schwann cells
    Zhang, Deteng
    Xu, Shengjun
    Wu, Sai
    Gao, Changyou
    JOURNAL OF MATERIALS CHEMISTRY B, 2018, 6 (08) : 1226 - 1237
  • [30] The effect of blending poly (L-lactic acid) on in vivo performance of 3D-printed poly(L-lactide-co-caprolactone)/PLLA scaffolds
    Duan, Ruiping
    Wang, Yimeng
    Su, Danning
    Wang, Ziqiang
    Zhang, Yiyun
    Du, Bo
    Liu, Lingrong
    Li, Xuemin
    Zhang, Qiqing
    BIOMATERIALS ADVANCES, 2022, 138